Showing results (1-10 of 19) with videos related to
Sort By:
Pageof 2
CNS Drugs|December 8, 2004
Remifentanil update: clinical science and utilityRichard Beers, Enrico CamporesiCancer Research|August 5, 2008
Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activityXing Du, Richard Beers, David J Fitzgerald, et al.Journal of Clinical Anesthesia|September 7, 2013
Medication injection safety knowledge and practices among anesthesiologists: New York State, 2011Prabhu Gounder, Richard Beers, Katherine Bornschlegel, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 12, 2002
Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage displayGiuliana Salvatore, Richard Beers, Inger Margulies, et al.Proceedings of the National Academy of Sciences of the United States of America|August 6, 2008
An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopesMasanori Onda, Richard Beers, Laiman Xiang, et al.Toxins|June 9, 2018
Domain II of Pseudomonas Exotoxin Is Critical for Efficacy of Bolus Doses in a Xenograft Model of Acute Lymphoblastic LeukemiaFabian Müller, Tyler Cunningham, Richard Beers, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 7, 2010
A recombinant immunotoxin targeting CD22 with low immunogenicity, low nonspecific toxicity, and high antitumor activity in miceJohanna K Hansen, John E Weldon, Laiman Xiang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Novel anti-CD30 recombinant immunotoxins containing disulfide-stabilized Fv fragmentsSatoshi Nagata, Masanori Onda, Yoshito Numata, et al.Proceedings of the National Academy of Sciences of the United States of America|March 26, 2011
Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopesMasanori Onda, Richard Beers, Laiman Xiang, et al.Molecular Cancer Therapeutics|October 8, 2015
Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing TumorsRonit Mazor, Jingli Zhang, Laiman Xiang, et al.Pageof 2